Details for the presentation are as follows: | |
Date: | |
Time: | |
Link: | click HERE |
The webcast will also be available for viewing and replay under the Investor Relations tab of the Company’s website. |
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in combination with atezolizumab (Tecentriq®) in a separate Phase 2 trial for the treatment of non-small cell lung cancer.
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
For more information, contact:
Hans Schambye, CEO | |
+45 70 70 52 10 | |
Investors/US | Media/EU |
arr@lifesciadvisors.com | svonderweid@lifesciadvisors.com |
+1 617 430 7577 | +41 78 680 0538 |
Source:
2023 GlobeNewswire, Inc., source